{"id":"cetuximab-radioimmunotherapy","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Skin rash"},{"rate":"10-30%","effect":"Mucositis"},{"rate":"5-20%","effect":"Hypomagnesemia"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This treatment works by using cetuximab, a monoclonal antibody that binds to EGFR on cancer cells, and then attaching a radioactive payload to the antibody. The radioactive payload then destroys the cancer cells. This approach is designed to minimize damage to healthy cells while targeting and eliminating cancer cells.","oneSentence":"Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:25:34.826Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT01884259","phase":"PHASE2","title":"Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-05","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III","enrollment":100},{"nctId":"NCT01693159","phase":"NA","title":"Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades","status":"UNKNOWN","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2011-05","conditions":"Pain","enrollment":50},{"nctId":"NCT01245985","phase":"PHASE2","title":"TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors","status":"TERMINATED","sponsor":"Heidelberg University","startDate":"2010-11","conditions":"Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Oro-, Hypopharyngeal and Laryngeal Cancer","enrollment":8},{"nctId":"NCT01192087","phase":"PHASE1, PHASE2","title":"Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2012-06","conditions":"Adenoid Cystic Carcinoma","enrollment":49},{"nctId":"NCT01472653","phase":"PHASE2","title":"Treatment Selection According to Skin Reaction to Cetuximab","status":"UNKNOWN","sponsor":"Institute of Oncology Ljubljana","startDate":"2011-12","conditions":"Head and Neck Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erbitux"],"phase":"phase_2","status":"active","brandName":"Cetuximab Radioimmunotherapy","genericName":"Cetuximab Radioimmunotherapy","companyName":"Arbeitsgemeinschaft medikamentoese Tumortherapie","companyId":"arbeitsgemeinschaft-medikamentoese-tumortherapie","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload. Used for Colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}